Anxiety Disorders: A Global Strategic Business Report
San Jose, CA (Vocus/PRWEB) April 12, 2011
GIA announces the release of a comprehensive global report on Anxiety Disorders market. The global market for anxiety disorders is forecast to reach $5.9 billion by the year 2017. Key factors driving market growth include rising stress levels that are further augmented by the recent financial crisis, increasing incidence and prevalence of anxiety disorders, growing aging population globally, existence of significant unmet needs, and the development of novel therapeutics.
Stress is one of the most significant health issues of the twenty-first century, to the extent of being called a global epidemic. Anxiety is a normal reaction to stress, which helps one deal with tense situations in the office, study harder for an exam, or keep focus on an important speech. In general, it helps one cope. But when anxiety becomes an excessive, irrational dread of everyday situations, it turns into a disabling disorder. Anxiety disorders represent the most commonly occurring mental health condition, affecting individuals of all age groups. In the recent years, the number of people suffering from anxiety disorders increased considerably owing to the global financial crisis that resulted in rising unemployment rates, and increasing stress levels. Ever-increasing aging global population is also one of the factors responsible for the rapid increase in sales of central nervous system drugs. Major types of anxiety disorders with high prevalence include Social Anxiety Disorder, Post-Traumatic Stress Disorder, Generalized Anxiety Disorder, Panic Disorder, and Obsessive-Compulsive Disorder.
Anxiety therapy addresses and eliminates specific factors causing the disorder and inhibits their reoccurrence, thereby helping in restoring and maintaining normal health of the affected individuals. The first line of agents used for the treatment of anxiety includes Selective Serotonin Reuptake Inhibitors such as Lexapro (Escitalopram), Paxil (Paroxetine), Zoloft (Sertraline), and Prozac (Fluoxetine). The other medications prescribed consist of GABA analogues, including new antidepressant Remeron (Mirtazapine); and MAOIs including Parnate (Tranylcypromine) or Nardil (Phenelzine), Lyrica (Pregabalin) or Neurontin (Gabapentin). TCAs, including Imipramine; atypical anti-psychotics including Quetiapine; and Piperazines including hydroxyzine, are also used for the treatment of anxiety. However, these medications are known to cause various side effects and complications.
Despite being the foundation for pharmacological treatment pertaining to anxiety disorders, the response rate of serotonergic-based treatment is more often below the robust level. In addition, though an array of treatment options are available for treating anxiety disorders, about one-third of patients suffering from psychiatric conditions still do not respond to the drugs that are presently available in the market. There exists an ever-increasing need for developing medications that offer a faster onset of action as compared to the presently available drugs. The research projects being undertaken by companies partly focus on the conventional mode of action, such as adjustment of nor-adrenaline and serotonin levels in the brain, and partly on unique and new mechanism. Physicians are looking at novel drugs for the treatment of anxiety disorders.
The existence of Neurokinin (NK) receptor antagonists, along with Corticotrophin Releasing Factor (CRF) antagonists within the anxiety disorders pipeline, drew major interest from key market participants. The NK receptor antagonists are expected to emerge as promising drugs for the treatment of anxiety disorders. Further, the market is expected to witness a transformation, with anti-psychotic drugs expected to change the future landscape of the anxiety disorder drugs market. Manufacturers of antidepressants are expected to enhance their products' target patient potential, considering the higher co-morbidity between depression and anxiety.
The US represents the largest regional market for anxiety disorder therapeutics worldwide, as stated by the new market research report on Anxiety Disorders. The US registers the highest number of anxiety disorder cases annually. The country incurs a cost of over US$42 million per annum for anxiety disorders, which accounts for almost one-third of the overall cost for mental illnesses. About 27% of the European population suffers from brain disorders, with depression being the most prevalent health problem in several EU-Member States. However, Asia-Pacific is forecast to register the fastest growth during the analysis period, registering a compounded annual growth rate of more than 5.0% during 2009-2017.
Major players profiled in the report include AstraZeneca Plc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Forest Laboratories, Inc., GlaxoSmithKline Plc, H. Lundbeck A/S, Mylan Inc., Neurocrine Biosciences, Inc., Pfizer Inc., Ratiopharm, Sanofi-Aventis, Valeant Pharmaceuticals, Watson Laboratories, among others.
The research report titled “Anxiety Disorders: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the anxiety disorders therapeutics markets, current market trends, key growth drivers, leading drugs in the market, overview of pipeline drugs, recent product approvals/launches, recent industry activity, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for anxiety disorders therapeutics market for the years 2009 through 2017 for the following geographic markets - US, Europe, Asia-Pacific, and Rest of World. Also, a six-year (2003-2008) historic analysis is provided for additional perspective.
For more details about this comprehensive market research report, please visit – http://www.strategyr.com/Anxiety_Disorders_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/
# # #